|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fassina A, Cappellesso R and Fassan M:
Classification of non-small cell lung carcinoma in transthoracic
needle specimens using microRNA expression profiling. Chest.
140:1305–1311. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schepeler T: Emerging roles of microRNAs
in the Wnt signaling network. Crit Rev Oncog. 18:357–371. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang T, Hu Y, Ju J, Hou L, Li Z, Xiao D,
Li Y, Yao J, Wang C, Zhang Y and Zhang L: Downregulation of miR-522
suppresses proliferation and metastasis of non-small cell lung
cancer cells by directly targeting DENN/MADD domain containing 2D.
Sci Rep. 6:193462016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stoddart A, Wang J, Hu C, Fernald AA,
Davis EM, Cheng JX and Le Beau MM: Inhibition of WNT signaling in
the bone marrow niche prevents the development of MDS in the
Apc(del/+) MDS mouse model. Blood. 129:2959–2970. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iqbal MA, Arora S, Prakasam G, Calin GA
and Syed MA: MicroRNA in lung cancer: Role, mechanisms, pathways
and therapeutic relevance. Mol Aspects Med. 70:3–20. 2019.
View Article : Google Scholar
|
|
9
|
Mendell JT: miRiad roles for the miR-17-92
cluster in development and disease. Cell. 133:217–222. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hong S, Yu S, Li J, Yin Y, Liu Y, Zhang Q,
Guan H, Li Y and Xiao H: miR-20b displays tumor-suppressor
functions in papillary thyroid carcinoma by regulating the MAPK/ERK
signaling pathway. Thyroid. 26:1733–1743. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Chen D, Jin L, Liu J, Su Z, Li Y,
Gui Y and Lai Y: MicroRNA-20b-5p functions as a tumor suppressor in
renal cell carcinoma by regulating cellular proliferation,
migration and apoptosis. Mol Med Rep. 13:1895–1901. 2016.
View Article : Google Scholar
|
|
12
|
Li D, Ilnytskyy Y, Kovalchuk A, Khachigian
LM, Bronson RT, Wang B and Kovalchuk O: Crucial role for early
growth response-1 in the transcriptional regulation of miR-20b in
breast cancer. Oncotarget. 4:1373–1387. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang B, Yang J and Xiao B: MicroRNA-20b
(miR-20b) promotes the proliferation, migration, invasion, and
tumorigenicity in esophageal cancer cells via the regulation of
phosphatase and tensin homologue expression. PLoS One.
11:e01641052016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu J, Chen L, Zou L, Yang P, Wu R, Mao Y,
Zhou H, Li R, Wang K, Wang W, et al: miR-20b, -21, and -130b
inhibit PTEN expression resulting in B7-H1 over-expression in
advanced colorectal cancer. Hum Immunol. 75:348–353. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Landais S, Landry S, Legault P and Rassart
E: Oncogenic potential of the miR-106-363 cluster and its
implication in human T-cell leukemia. Cancer Res. 67:5699–5707.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hoppler S and Kavanagh CL: Wnt signalling:
Variety at the core. J Cell Sci. 120:385–393. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Z, Shah K, Busby T, Giles K,
Khodadadi-Jamayran A, Li W and Jiang H: Hijacking a key chromatin
modulator creates epigenetic vulnerability for MYC-driven cancer. J
Clin Invest. 128:3605–3618. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dejure FR and Eilers M: MYC and tumor
metabolism: Chicken and egg. EMBO J. 36:3409–3420. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Beà S: Cyclin D1 transcriptional
activation in MCL. Blood. 123:1979–1980. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Duan FG, Wang MF, Cao YB, Dan Li, Li RZ,
Fan XX, Khan I, Lai HL, Zhang YZ, Hsiao WW, et al MicroRNA-421
confers paclitaxel resistance by binding to the KEAP1 3′UTR and
predicts poor survival in non-small cell lung cancer. Cell Death
Dis. 10:8212019. View Article : Google Scholar
|
|
24
|
Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu
VW, Albacker L, Stephens PJ, Miller VA and Ali SM: Emergence of
novel and dominant acquired EGFR solvent-front mutations at Gly796
(G796S/R) together with C797S/R and L792F/H mutations in one EGFR
(L858R/T790M) NSCLC patient who progressed on osimertinib. Lung
Cancer. 108:228–231. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang T, Alvarez AA, Pangeni RP, Horbinski
CM, Lu S, Kim SH, James CD, J Raizer JA, Kessler J, Brenann CW, et
al: A regulatory circuit of miR-125b/miR-20b and Wnt signalling
controls glioblastoma phenotypes through FZD6-modulated pathways.
Nat Commun. 7:128852016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamada N, Noguchi S, Mori T, Naoe T, Maruo
K and Akao Y: Tumor-suppressive microRNA-145 targets catenin δ-1 to
regulate Wnt/β-catenin signaling in human colon cancer cells.
Cancer Lett. 335:332–342. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Trautmann M, Sievers E, Aretz S, Kindler
D, Michels S, Friedrichs N, Renner M, Kirfel J, Steiner S, Huss S,
et al: SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a
therapeutic target in synovial sarcoma. Oncogene. 33:5006–5016.
2014. View Article : Google Scholar
|
|
28
|
Silva J, Garcia V, Zaballos Á, Provencio
M, Lombardía L, Almonacid L, García JM, Domínguez G, Peña C, Diaz
R, et al Vesicle-related microRNAs in plasma of nonsmall cell lung
cancer patients and correlation with survival. Eur Respir J.
37:617–623. 2011. View Article : Google Scholar
|
|
29
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nusse R and Clevers H: Wnt/β-catenin
signaling, disease, and emerging therapeutic modalities. Cell.
169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen Q, Cao HZ and Zheng PS: LGR5 promotes
the proliferation and tumor formation of cervical cancer cells
through the Wnt/β-catenin signaling pathway. Oncotarget.
5:9092–9105. 2014.PubMed/NCBI
|
|
32
|
Shen G, Jia H, Tai Q, Li Y and Chen D:
miR-106b downregulates adenomatous polyposis coli and promotes cell
proliferation in human hepatocellular carcinoma. Carcinogenesis.
34:211–219. 2013. View Article : Google Scholar
|
|
33
|
Li M, Tian L, Wang L, Yao H, Zhang J, Lu
J, Sun Y, Gao X, Xiao H and Liu M: Down-regulation of miR-129-5p
inhibits growth and induces apoptosis in laryngeal squamous cell
carcinoma by targeting APC. PLoS One. 8:e778292013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Korinek V, Barker N, Morin PJ, van Wichen
D, de Weger R, Kinzler KW, Vogelstein B and Clevers H: Constitutive
transcriptional activation by a beta-catenin-Tcf complex in
APC-/- colon carcinoma. Science. 275:1784–1787. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gaspar C, Franken P, Molenaar L, Breukel
C, van der Valk M, Smits R and Fodde R: A targeted constitutive
mutation in the APC tumor suppressor gene underlies mammary but not
intestinal tumorigenesis. PLoS Genet. 5:e10005472009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Janssens N, Janicot M and Perera T: The
Wnt-dependent signaling pathways as target in oncology drug
discovery. Invest New Drugs. 24:263–280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yamada T and Masuda M: Emergence of TNIK
inhibitors in cancer therapeutics. Cancer Sci. 108:818–823. 2017.
View Article : Google Scholar : PubMed/NCBI
|
